Journals / Anadolu Kardiyoloji Dergisi / 2011 / Cilt: 11 - Sayı: 4

Hafif-orta birincil hipertansiyonda karvedilol ve nebivolol'ün antihipertansif etkinliğinin karşılaştırılması: Bir randomize çalışma

Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial

Pages
310–313
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mean heart rate was significantly decreased after commencing both carvedilol (70.2±5.2 bpm) and nebivolol (64.9±3.9 bpm) treatments compared to placebo (78.8±5.2 bpm) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of the present study is to compare the antihypertensive effects of carvedilol and nebivolol in mild to moderate hypertensive patients.Methods: It is a prospective; placebo-controlled, cross-over, double-blind, randomized, single-center clinical trial.
📊
Key Findings & Data:Patients (n=20) who were first diagnosed with mild to moderate systemic hypertension according to mean ambulatory blood pressure measurements > 130/85 mmHg and no previous antihypertensive therapy were prospectively enrolled into the study.
💡
Conclusion & Impact:Mean heart rate was significantly decreased after commencing both carvedilol (70.2±5.2 bpm) and nebivolol (64.9±3.9 bpm) treatments compared to placebo (78.8±5.2 bpm) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of the present study is to compare the antihypertensive effects of carvedilol and nebivolol in mild to moderate hypertensive patients.Methods: It is a prospective; placebo-controlled, cross-over, double-blind, randomized, single-center clinical trial. Patients (n=20) who were first diagnosed with mild to moderate systemic hypertension according to mean ambulatory blood pressure measurements > 130/85 mmHg and no previous antihypertensive therapy were prospectively enrolled into the study. After 10 days of placebo run-in period, they were randomized within the same group as cross-over design to one month carvedilol 25 mg and one month nebivolol 5 mg regimen given once daily in the morning. The primary outcome variables were systolic and diastolic blood pressures determined by 24-hour ambulatory blood pressure measurements. Mutlivariate analysis of variance for repeated measurements with 3x2 factorial design was used for statistical analysis of results.Results: The study group consisted of 6 women and 14 men whose mean age was 42.9±12.8 years (range 19-63 years). Mean heart rate was significantly decreased after commencing both carvedilol (70.2±5.2 bpm) and nebivolol (64.9±3.9 bpm) treatments compared to placebo (78.8±5.2 bpm) (p

Özet

Amaç: Karvedilol ve nebivolol'ün hafif-orta hipertansif hastalarda etkinliğini karşılaştırmaktır. Yöntemler: Plasebo kontrollü, prospektif, çapraz-geçişli ve çift-kör randomize olarak tek merkezde gerçekleştirilen çalışmada, ilk kez hipertansiyon tanısı almış 20 hipertansif hasta 24 saatlik ambulatuvar kan basıncı yöntemiyle takip edilmişlerdir. On günlük plasebo sonrası hastalar 5 mg nebivolol ve 25 mg karvedilol tedavilerine randomize edildiler. Primer sonlanım değişkenleri 24-saat ambulatuvar kan basıncı ile ölçülen sistolik ve diyastolik kan basınçları idi. Bulguların istatistiksel analizinde 3x2 faktoriyel dizaynlı tekrarlayan ölçümler için çoklu varyans analizi kullanıldı.Bulgular: Yaşları 43±13 olan 6 kadın, toplam 20 hasta çalışmaya alındı. Ortalama sistolik ve diyastolik kan basınçları karvedilol (133.8±9/86.6±8.6 mmHg), nebivolol (134±8.7/85.6±7.4 mmHg) tedavilerinde plaseboya göre anlamlı azaldı (143.9±8.9/94.4±9.2 mmHg, p0.05). Hem karvedilol, hem nebivolol tedavileri sırasında hiçbir yan etki gözlemlenmedi.Sonuç: Plaseboya göre anlamlı düzeyde kan basıncını azaltmalarına karşın karvedilol ve nebivolol'ün birbirine üstünlüğü saptanamadı.

🔖

Cite This Article

ALTUN, A., ERDOĞAN, O., ERTEM, B. (2022). Hafif-orta birincil hipertansiyonda karvedilol ve nebivolol'ün antihipertansif etkinliğinin karşılaştırılması: Bir randomize çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 11 - Sayı: 4, 310–313. https://ajindex.com/articles/436690

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Opie L, Yusuf S. Beta-blocking agents. In: Opie LH, Gersh B editors. Drugs for the Heart. 6th ed. Philadelphia: W.B. Saunders Company; 2005. p. 1-32
  2. Cockcroft JR. Exploring vascular benefits of endothelium-derived nitric-oxide. Am J Hypertens 2005;18 (Suppl):177S-83S
  3. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for l-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71
  4. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511-4. doi:10.1161/hc3001.094207 5. Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA. Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1988; 1: 91-6
  5. Sarafidis PA, Bakris GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens 2007; 25: 249-52. doi:10.1097/HJH.0b013e3280104fa5 7. Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag 2006; 2: 303-8. doi:10.2147/vhrm.2006.2.3.303 8. Sica DA. Beta-blockers in hypertension: A reassessment of the benefit of combined alpha-/beta-blockade. J Clin Hypertens (Greenwich) 2007; 9: 4-9. doi:10.1111/j.1524-6175.2007.06623.x 9. Van Neuten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomized trial. J Hum Hypertens 1997; 11: 813-9
  6. Czuriga I, Riecansky I, Bodnar J, Fulop T, Kruzsicz V, Kristof E, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 2003; 17: 257-63. doi:10.1023/A:1026180325278 11. Van Neuten L, Taylor FR, Robertson JI. Nebivolol vs. atenolol and placebo in essential hypertension: a double-blind randomized trial. J Hum Hypertens 1998; 12: 135-40
  7. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69
  8. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-36. doi:10.1001/jama.292.18.2227